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Psychiatric disorders affect approximately 1 in 4 people. 
Two  articles  published  today  in  BMC  Biology  [1,2] 
discuss prospects for an improved understanding of their 
biology and treatment, informed by recent and ongoing 
advances  in  defining  the  genetic  architecture  that 
underlies them.
Although  neuropsychiatric  diseases  show  substantial 
heritability, their inheritance is not simple. As for other 
common  diseases  that  do  not  show  simple  Mendelian 
inheritance,  the  prevailing  hypothesis  of  the  last  half-
century  has  been  that  many  common  alleles,  each  of 
modest  effect,  combine  with  environmental  factors  to 
cause disease. For neuropsychiatric disorders, however, 
this thinking has been challenged by recent findings of an 
increasing  number  of  rare  mutations  that  have  a  large 
effect on disease susceptibility.
In their review article [1], Kevin Mitchell, Josh Huang, 
Bita Moghaddam and Akira Sawa lay out a framework for 
studying  the  effects  of  these  rare  variants  in  animals, 
explaining why they see this as the best way to model 
psychiatric  disease.  Previously,  animal  models  were 
developed on the basis of behavioral assays that appeared 
to represent some aspect of psychopathology, and viewed 
as valid when the behaviors in question were modified by 
medication used to treat the disease. Such models have 
yielded few new drugs, whereas modeling causal genetic 
variants  in  animals  offers  the  possibility  of  identifying 
disease pathology at multiple levels and developmental 
timepoints,  and  the  hope  of  new  targets  of  direct 
relevance for therapeutic intervention in humans.
In a separate article [2], Aiden Corvin, a psychiatrist 
and  member  of  the  Psychiatric  Genetics  Consortium 
responsible for recent genome-wide association studies 
(GWAS)  on  psychiatric  disease,  considers  the  implica-
tions of recent genetic findings for schizophrenia patients. 
Currently,  schizophrenia  is  diagnosed  on  the  basis  of 
combinations of symptoms, no one of which is on its own 
specifically  diagnostic  of  schizophrenia;  and  the  few 
treatments available are only partially effective, and only 
in a subset of patients. Corvin looks to a future in which 
diagnosis  will  be  guided  by  molecular  etiology,  and 
patients may be treated with drugs known to be effective 
for the particular genetic subtype of disease.
One of the most striking findings of the genetic studies 
is  that  individual  rare  mutations  of  large  effect  often 
confer  susceptibility  to  more  than  one  disorder,  for 
example  both  schizophrenia  and  autism.  Overlap  in 
susceptibility is also seen in the GWAS that have to date 
identified  10  common  variants  with  small  effects  on 
disease risk, though here the major overlap is seen with 
bipolar  disorder.  These  findings  are  consistent  with 
epidemiological  studies  that  indicate  shared  risk  for 
different disorders, and families in which a spectrum of 
disorders is observed. The strong association of different 
disorders with the same mutation suggests they can be 
distinct  phenotypic  endpoints  that  can  arise  from  a 
common genetic origin, rather than a polygenic effect, a 
possibility  that  can  be  explored  using  the  modeling 
approach  outlined  by  Mitchell  and  colleagues.  Corvin 
concludes  from  this  accumulating  evidence  that 
schizophrenia will not continue to be viewed as a single 
disease.
In one respect there is a notable difference in the stance 
taken by the two articles. Mitchell and coauthors espouse 
the  proposition,  gaining  ground  of  late  [3,  4],  that  the 
disease-associated rare variants reported so far (mostly 
short deletions or duplications) represent only the tip of 
the iceberg, and that as sequencing studies uncover more 
functionally  relevant  mutations,  most  cases  of  neuro-
psychiatric  disease  will  be  found  to  be  attributable,  in 
large part, to single rare mutations of large effect. Corvin 
on the other hand takes the view that with only 5% of 
cases so far explained by rare mutations, it is too early to 
judge to what extent they account for the heritability of 
the  disease,  and  that  the  combined  effect  of  common 
alleles,  together  with  environmental  factors,  may  still 
explain  a  considerable  fraction  of  cases  [5].  These  two 
different outlooks reflect a lively and ongoing debate on 
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value of proceeding to yet bigger GWAS studies in an 
effort to identify more common risk loci, and to what 
extent  common  risk  variants  may  actually  be  tagging 
linked rare mutations responsible for the association with 
disease [6, 7]. The expectation is that answers will come 
with  the  increasing  number  of  patient  genomes  or 
exomes  being  sequenced,  alongside  those  of  family 
members – though this is not without difficulties, as a 
typical person is estimated to carry about 150 rare coding 
variants affecting about 1% of his or her genes, making it 
a challenge to identify those with a causal role in disease.
Wherever the final balance lies, there is agreement that 
the rare mutations of large effect provide a much-needed 
entry  point  to  get  at  the  underlying  biology  of  these 
disorders. The hope is that despite the heterogeneity of 
primary  genetic  causes,  systematic  analyses  in  animal 
models, using the sophisticated neurogenetic tools now 
available,  will  identify  a  convergence  of  pathogenic 
mechanisms that can be targeted therapeutically.
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